Koers Relief Therapeutics Holding AG Other OTC
Aandelen
RLFTF
CH0100191136
Biotechnologie & Medisch Onderzoek
Omzet 2022 | 6,08 mln. 6,74 mln. 6,21 mln. | Omzet 2023 | 6,03 mln. 6,68 mln. 6,16 mln. | Marktkapitalisatie | 24,96 mln. 27,64 mln. 25,48 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -50 mln. -55,38 mln. -51,05 mln. | Nettowinst (verlies) 2023 | -98 mln. -109 mln. -100 mln. | EV/omzet 2022 | 19,3 x |
Nettoliquiditeiten 2022 | 14,89 mln. 16,5 mln. 15,21 mln. | Nettoliquiditeiten 2023 | 10,25 mln. 11,36 mln. 10,47 mln. | EV/omzet 2023 | 2,44 x |
K/w-verhouding 2022 |
-2,5
x | K/w-verhouding 2023 |
-0,24
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 65,87% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Michelle Lock
CEO | Chief Executive Officer | 55 | 28-01-22 |
Ram Selvaraju
CHM | Chairman | 45 | 25-05-16 |
Anthony M. Kim
PRN | Corporate Officer/Principal | - | 01-12-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ram Selvaraju
CHM | Chairman | 45 | 25-05-16 |
Paolo Galfetti
PRN | Corporate Officer/Principal | 59 | 27-05-21 |
Michelle Lock
CEO | Chief Executive Officer | 55 | 28-01-22 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+43,36% | 54,63 mld. | |
-5,31% | 39,92 mld. | |
+14,75% | 26,86 mld. | |
-12,56% | 26,22 mld. | |
-22,45% | 18,78 mld. | |
+25,12% | 12,21 mld. | |
+0,04% | 12,16 mld. | |
+26,04% | 11,94 mld. | |
-11,83% | 10,74 mld. |